Abstract
Abstract
Purpose of Review
The use of psychedelics in a therapeutical setting has been reported for the treatment of various diagnoses in recent years. However, as psychedelic substances are still commonly known for their (illicit) recreational use, it may seem counterintuitive to use psychedelic therapy to treat substance use disorders. This review aims to discuss how psychedelics can promote and intensify psychotherapeutic key processes, in different approaches like psychodynamic and cognitive behavioral therapy, with a spotlight on the treatment of substance use disorders (SUD).
Recent Findings
There is promising evidence of feasibility, safety, and efficacy of psychedelic therapy in SUD. In the whole process of former and current psychedelic therapy regimes that have shown to be safe and efficacious, various psychotherapeutic elements, both psychodynamic and behavioral as well as other approaches, can be identified, while a substantial part of the assumed mechanism of action, the individual psychedelic experience, cannot be distinctly classified to just one approach.
Summary
Psychedelic therapy consists of a complex interaction of pharmacological and psychological processes. When administered in well-defined conditions, psychedelics can serve as augmentation of different psychotherapy interventions in the treatment of SUD and other mental disorders, regardless of their theoretical origin.
Funder
Charité - Universitätsmedizin Berlin
Publisher
Springer Science and Business Media LLC
Subject
Psychiatry and Mental health,Clinical Psychology
Reference107 articles.
1. Nichols DE. Psychedelics. Pharmacol Rev. 2016;68(2):264–355. https://doi.org/10.1124/pr.115.011478.
2. EDR: European Monitoring Centre for Drugs and Drug Addiction. European drug report 2017: trends and developments. http://www.emcdda.europa.eu/publications/edr/trends-developments/2017 (2017). Accessed 15.02.2021 2021.
3. van Amsterdam J, Nutt D, Phillips L, van den Brink W. European rating of drug harms. J Psychopharmacol. 2015;29(6):655–60. https://doi.org/10.1177/0269881115581980.
4. Johnson MW, Richards WA, Griffiths RR. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22(6):603–20.
5. Garcia-Romeu A, Davis AK, Erowid E, Griffiths RR, Johnson MW. Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: an online survey. Front Psych. 2020;10:955.
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献